Conference call to discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF will be held on November 13 at 4:30 pm. Webcast Link
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TENX:
- Tenax Therapeutics Reports Increased R&D Expenses Amid Clinical Trials
- Tenax Therapeutics reports Q3 EPS (40c), consensus ($1.12)
- TENX Earnings this Week: How Will it Perform?
- Tenax Therapeutics Advances Phase 3 Study on Levosimendan for PH-HFpEF
- Tenax Therapeutics management to meet with Piper Sandler